BioCryst Pharma (BCRX) PT Raised to $15 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Rating Summary:
16 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Jefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $15.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "BCRX to acquire ATXS for $13/sh at +53% premium to yesterday's close for long-acting (Q3M/Q6M) HAE drug navenibart for total equity value of $920M. Transaction has been approved by both cos BODs and expected to close 1Q26. Naven top-line ph.III data are expected early'27. BCRX believes they can reach +15% CAGR in Orladeyo+naven sales over the next decade to get est $1.8B+ by 2033 w/ $1B+ cash by 2029. We added naven to our model (50% POS). PT to $15."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oil States International (OIS) PT Lowered to $11 at Raymond James
- Citi raises General Dynamics price target to $400, keeps Neutral
- Norwegian Cruise (NCLH) PT Raised to $22 at Freedom Broker, Upgrades to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Jefferies & Co, Definitive Agreement, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
